TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18514770

Group type: EXPERIMENTAL
Intervention: Urine tumor-associated trypsin inhibitor (TATI)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: CYFRA 21-1
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Urinary bladder carcinoma antigen (UBC)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: TATI
Number of subjects: 160
Study: 16873788

Group type: EXPERIMENTAL
Intervention: Physiological and laboratory outcomes
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Patient-important outcomes
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Surrogate outcomes
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Laboratory investigations
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Nonprofit funding source
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Measure of physiological and laboratory outcomes
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Cross-over design
Number of subjects: 199
Study: 12560298

Group type: EXPERIMENTAL
Intervention: remifentanil 3 microg x kg(‐1) followed by propofol 2 mg x kg(‐1) (Group I)
Number of subjects: 45

Group type: COMPARATOR
Intervention: thiopentone 6 mg x kg(‐1) (Group II)
Number of subjects: 45

Group type: COMPARATOR
Intervention: etomidate 0.3 mg x kg(‐1) (Group III)
Number of subjects: 45
Study: 10868866

Group type: COMPARATOR
Intervention: intensive insulin therapy + placebo (C) (n = 12)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: intensive insulin therapy + nicotinamide, 700 mg three times a day (NIC) (n = 11)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 72‐h intravenous insulin followed by intensive insulin therapy + nicotinamide, 700 mg three times a day (NIV) (n = 11)
Number of subjects: 34
Study: 9413735

Group type: EXPERIMENTAL
Intervention: Sodium citrate (0.3 g (kg body mass)‐1) 3 h before exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (CaCO3)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High-CHO diet (81 +/‐ 2% CHO, 13 +/‐ 2% protein, 6 +/‐ 1% fat)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Normal diet (54 +/‐ 7% CHO, 13 +/‐ 2% protein, 33 +/‐ 7% fat)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sodium citrate and placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All experimental conditions
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sodium citrate
Number of subjects: 6
Study: 8105519

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 35

Group type: COMPARATOR
Intervention: Inhaled terbutaline and salbutamol
Number of subjects: 35
Study: 3517081

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diazepam (0.3 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Caffeine and Diazepam combination
Number of subjects: 6
Study: 30570529

Group type: EXPERIMENTAL
Intervention: MRI-PDFF
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: CAP
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: SteatoTest
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: APRI
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: FIB-4
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: alanine aminotransferase ≥36 IU/L
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: NashTest
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: FibroScan
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: FibroTest
Number of subjects: 402
Study: 29925489

Group type: EXPERIMENTAL
Intervention: Bictegravir (50 mg), Emtricitabine (200 mg), Tenofovir Alafenamide (25 mg)
Number of subjects: 563

Group type: COMPARATOR
Intervention: Dolutegravir, Abacavir, Lamivudine
Number of subjects: 563
Study: 27510017

Group type: EXPERIMENTAL
Intervention: Propolis mouthwash
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diluted water (control)
Number of subjects: 40
Study: 25415777

Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine
Number of subjects: 32

Group type: COMPARATOR
Intervention: 0.2% ropivacaine
Number of subjects: 32
Study: 22585774

Group type: EXPERIMENTAL
Intervention: Oral dimenhydrinate (1 mg/kg; maximum: 50 mg) every 6 hours for 4 doses
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo for 4 doses
Number of subjects: 144
Study: 20955625

Group type: EXPERIMENTAL
Intervention: Habitual snoring prevalence
Number of subjects: 20152

Group type: EXPERIMENTAL
Intervention: Lower family income
Number of subjects: 20152

Group type: EXPERIMENTAL
Intervention: Lower father's education
Number of subjects: 20152

Group type: EXPERIMENTAL
Intervention: Breastfeeding duration < 6 months
Number of subjects: 20152

Group type: EXPERIMENTAL
Intervention: Pregnancy maternal smoking
Number of subjects: 20152

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 20152

Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 20152

Group type: EXPERIMENTAL
Intervention: Chronic/allergic rhinitis
Number of subjects: 20152

Group type: EXPERIMENTAL
Intervention: Asthma
Number of subjects: 20152

Group type: EXPERIMENTAL
Intervention: Adenotonsillar hypertrophy
Number of subjects: 20152

Group type: EXPERIMENTAL
Intervention: Chronic otitis media
Number of subjects: 20152

Group type: EXPERIMENTAL
Intervention: Family history of habitual snoring
Number of subjects: 20152
Study: 17570789

Group type: EXPERIMENTAL
Intervention: Lymphatic sparing (LS) technique with patent blue V dye (2 mL injected under the tunica dartos)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Lymphatic nonsparing (LNS) technique
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Lymphatic sparing (LS) technique
Number of subjects: 52
Study: 16279849

Group type: EXPERIMENTAL
Intervention: Subtotal thyroidectomy (leaving a small thyroid remnant)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Total thyroidectomy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Subtotal thyroidectomy
Number of subjects: 44
Study: 12376274

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone injections at 10 mg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Normal saline (2 ml)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Total incidence of nausea and vomiting
Number of subjects: 84
Study: 10553972

Group type: EXPERIMENTAL
Intervention: Aminoleban EN (branched-chain amino acids) with normal diet for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (isonitrogenous and isocaloric diet only)
Number of subjects: 50
Study: 8672313

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid progesterone concentration in the third trimester and term groups
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid progesterone concentration in the second trimester group
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Maximum cephalad spread of analgesia in the second trimester, third trimester, and term groups
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid progesterone concentration
Number of subjects: 134
Study: 2177614

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no GM-CSF)
Number of subjects: 10
Study: 7437265

Group type: EXPERIMENTAL
Intervention: 100 mg dapsone (DDS) + 25 mg pyrimethamine (PYR)
Number of subjects: 7

Group type: COMPARATOR
Intervention: 100 mg dapsone (DDS)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: In vitro studies of plasma protein DDS binding
Number of subjects: 7
Study: 30267864

Group type: COMPARATOR
Intervention: Infliximab monotherapy (5 mg/kg)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Combination therapy with infliximab and azathioprine (2.5 mg/kg/day)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Combination therapy with infliximab and azathioprine
Number of subjects: 206

Group type: COMPARATOR
Intervention: Infliximab monotherapy
Number of subjects: 206
Study: 28648969

Group type: EXPERIMENTAL
Intervention: Generic Self-Help (GENERIC)
Number of subjects: 2900

Group type: EXPERIMENTAL
Intervention: e-cigarette Targeted Self-Help (eTARGET)
Number of subjects: 2900

Group type: COMPARATOR
Intervention: Assessment Only (ASSESS)
Number of subjects: 2900
Study: 25598475

Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine
Number of subjects: 2089
Study: 23288282

Group type: EXPERIMENTAL
Intervention: Auriculotherapy (true stimulation)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Sham auriculotherapy (placebo)
Number of subjects: 125
Study: 21335787

Group type: EXPERIMENTAL
Intervention: Technical practice (simulation training group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Knowledge retention alone group (listening to the didactic lesson without training)
Number of subjects: 24
Study: 19756557

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 482

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 482
Study: 17903626

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 238
Study: 15459609

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment combined with streptokinase (HBO+)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Streptokinase alone (HBO‐)
Number of subjects: 74
Study: 11189826

Group type: EXPERIMENTAL
Intervention: Targeted mailed intervention informing about Medicare mammogram benefits
Number of subjects: 1839

Group type: COMPARATOR
Intervention: Control group (untreated cohorts)
Number of subjects: 1839
Study: 9261526

Group type: EXPERIMENTAL
Intervention: Glutathione (GSH)
Number of subjects: 151
Study: 8290669

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Haloperidol (short-term)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Haloperidol (long-term)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 2964548

Group type: EXPERIMENTAL
Intervention: E‐10‐hydroxy‐NT
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: NA infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: E‐10‐hydroxy‐NT and NT
Number of subjects: 8
Study: 31526307

Group type: EXPERIMENTAL
Intervention: Dark chocolate (1 mg/g of body weight)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Milk chocolate
Number of subjects: 100
Study: 29173128

Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy (CBT) plus an individually tailored intervention module focused on cognitive conflicts (CCs)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Group plus individual CBT
Number of subjects: 104
Study: 28391619

Group type: EXPERIMENTAL
Intervention: Ciclosporin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciclosporin (for patients with large lesions ≥ 20 cm2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciclosporin (for the majority of patients with smaller lesions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 0
Study: 25916088

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 14
Study: 23834159

Group type: EXPERIMENTAL
Intervention: Fructose-reduced diet (FRD) for 4 weeks after a 2-week run-in on IBS diet
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group (no fructose-reduced diet)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Fructose breath test (FBT)
Number of subjects: 182
Study: 20705795

Group type: EXPERIMENTAL
Intervention: Simulation-based plus video training
Number of subjects: 47

Group type: COMPARATOR
Intervention: Video training alone
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: MICU (post-intervention)
Number of subjects: 47

Group type: COMPARATOR
Intervention: SICU (no intervention)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Post-intervention MICU
Number of subjects: 47
Study: 19499865

Group type: EXPERIMENTAL
Intervention: Coopdech blocker
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Arndt blocker
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Univent tube
Number of subjects: 120

Group type: COMPARATOR
Intervention: double-lumen tube
Number of subjects: 120
Study: 16690968

Group type: EXPERIMENTAL
Intervention: Rituximab/CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 362
Study: 15533586

Group type: EXPERIMENTAL
Intervention: Isolated IFG
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Isolated IGT
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Both IFG and IGT
Number of subjects: 627
Study: 11136953

Group type: COMPARATOR
Intervention: DASH diet with high sodium
Number of subjects: 412

Group type: COMPARATOR
Intervention: DASH diet with low sodium
Number of subjects: 412

Group type: COMPARATOR
Intervention: Control diet with high sodium to intermediate sodium
Number of subjects: 412

Group type: COMPARATOR
Intervention: Control diet with intermediate sodium to low sodium
Number of subjects: 412

Group type: COMPARATOR
Intervention: DASH diet with intermediate sodium to low sodium
Number of subjects: 412

Group type: COMPARATOR
Intervention: DASH diet with high sodium to intermediate sodium
Number of subjects: 412
Study: 9630383

Group type: EXPERIMENTAL
Intervention: Margarines enriched in soybean oil sterol‐esters
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Margarines enriched in sitostanol‐ester
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control margarine (non‐enriched)
Number of subjects: 100
Study: 7530697

Group type: EXPERIMENTAL
Intervention: Single doses of L-697,639 (25 mg to 500 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple doses of L-697,639 (up to 100 mg every 12 h for ten days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single doses of L-697,639 (200 mg and 500 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single doses of L-697,639 (25 mg and 500 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple doses of L-697,639
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 500 mg dose of L-697,639
Number of subjects: 0
Study: 3042150

Group type: EXPERIMENTAL
Intervention: Immediate mobilization
Number of subjects: 300

Group type: COMPARATOR
Intervention: Bed rest for 6 hours (3 hours prone followed by 3 hours supine)
Number of subjects: 300
Study: 30658270

Group type: EXPERIMENTAL
Intervention: Maternal fetal attachment (MFA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Maternal depression
Number of subjects: 36

Group type: COMPARATOR
Intervention: Parenting stress
Number of subjects: 36
Study: 28750610

Group type: EXPERIMENTAL
Intervention: CR + BCAA
Number of subjects: 0

Group type: COMPARATOR
Intervention: CR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCAA without CR
Number of subjects: 0
Study: 26359611

Group type: EXPERIMENTAL
Intervention: Manual-based staff training programme delivered by a small intervention team
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study: 22329426

Group type: EXPERIMENTAL
Intervention: Sadness mood induction
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Shame mood induction
Number of subjects: 300

Group type: COMPARATOR
Intervention: Neutral mood induction
Number of subjects: 300
Study: 21839410

Group type: EXPERIMENTAL
Intervention: Paper version of the PRO instrument
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web version of the PRO instrument
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interactive voice response system version of the PRO instrument
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interview version of the PRO instrument
Number of subjects: 0

Group type: COMPARATOR
Intervention: All versions of the PRO instrument
Number of subjects: 0
Study: 19886856

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 14
Study: 16915310

Group type: EXPERIMENTAL
Intervention: Mindfulness training (8-week course)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study: 14980912

Group type: EXPERIMENTAL
Intervention: Early ambulation (Group E)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 6-hour ambulation (Group 6-h)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Late ambulation (Group L)
Number of subjects: 120
Study: 11258773

Group type: EXPERIMENTAL
Intervention: 2 cm excision margin
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: 4 cm excision margin
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Ulceration present
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Ulceration absent
Number of subjects: 740

Group type: COMPARATOR
Intervention: Observation of regional lymph nodes
Number of subjects: 740

Group type: COMPARATOR
Intervention: Elective node dissection of regional lymph nodes
Number of subjects: 740
Study: 9152564

Group type: EXPERIMENTAL
Intervention: finasteride
Number of subjects: 2112

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2112
Study: 7898078

Group type: EXPERIMENTAL
Intervention: Simvastatin 2.5 mg
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Simvastatin 5 mg
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 3278234

Group type: EXPERIMENTAL
Intervention: Silver nitrate drops
Number of subjects: 2732

Group type: EXPERIMENTAL
Intervention: Tetracycline ointment
Number of subjects: 2732
Study: 29673408

Group type: EXPERIMENTAL
Intervention: Hydrosurgery
Number of subjects: 137

Group type: COMPARATOR
Intervention: Conventional tangential excision with a knife
Number of subjects: 137
Study: 28501369

Group type: EXPERIMENTAL
Intervention: SCREENIVF
Number of subjects: 851
Study: 25616822

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (PCB)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control (no paclitaxel)
Number of subjects: 154
Study: 23756271

Group type: EXPERIMENTAL
Intervention: 50 µg oral misoprostol (two 25 µg tablets)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: 25 µg intravaginal misoprostol (one 25 µg tablet)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 228
Study: 21356121

Group type: EXPERIMENTAL
Intervention: Access to water (intervention group)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Thickened fluids (control group)
Number of subjects: 76
Study: 18172906

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 22431674

Group type: EXPERIMENTAL
Intervention: Peer mentoring group
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Financial incentives group
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 118
Study: 16022955

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (METS)
Number of subjects: 11323

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 11323

Group type: EXPERIMENTAL
Intervention: Weight reduction (moderate: -6% to -10%; substantial: >-10%)
Number of subjects: 11323

Group type: EXPERIMENTAL
Intervention: Weight gain
Number of subjects: 11323
Study: 12701817

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (30 g per day for 14 days)
Number of subjects: 12
Study: 10462113

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8900567

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 100
Study: 2132029

Group type: EXPERIMENTAL
Intervention: High nitrogen infusion (0.3 g/body weight kg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low nitrogen infusion (0.1 g/body weight kg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Patients with complications (both nitrogen groups)
Number of subjects: 20
Study: 347954

Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 9
Study: 11981237

Group type: EXPERIMENTAL
Intervention: Ketamine (subanesthetic doses)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31374665

Group type: EXPERIMENTAL
Intervention: hunova® rehabilitation robot
Number of subjects: 0
Study: 30170593

Group type: EXPERIMENTAL
Intervention: Heated tobacco products (HTPs)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional cigarettes
Number of subjects: 12
Study: 27525939

Group type: EXPERIMENTAL
Intervention: Upland cotton genotypes
Number of subjects: 16
Study: 24907873

Group type: EXPERIMENTAL
Intervention: levobupivacaine 6.75 mg + 0.3 mL 2% lidocaine (Group L)
Number of subjects: 40

Group type: COMPARATOR
Intervention: levobupivacaine 6.75 mg + saline (Group C)
Number of subjects: 40
Study: 22215866

Group type: EXPERIMENTAL
Intervention: Active anodal tDCS (2 mA, 15 sessions over 3 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 64
Study: 20308916

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion during cardiopulmonary bypass (CPB)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Saline infusion (control) during cardiopulmonary bypass (CPB)
Number of subjects: 106
Study: 18803987

Group type: EXPERIMENTAL
Intervention: Exenatide 5 microg
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Exenatide 10 microg
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 15994073

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12830056

Group type: EXPERIMENTAL
Intervention: Radial artery
Number of subjects: 438

Group type: COMPARATOR
Intervention: Right internal thoracic artery
Number of subjects: 438

Group type: COMPARATOR
Intervention: Saphenous vein
Number of subjects: 438
Study: 11789170

Group type: EXPERIMENTAL
Intervention: Retention enema with Qilian Liquid (QLL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0